WHO recommends Epclusa, a Hepatitis C Combined Therapy in Just One Pill
The WHO’s EML is used by many countries to increase access to medicines and guide decisions about which products they ensure are available for their populations.
Sofosbuvir Reduces Transplant Need and Mortality Rates in Hepatitis C Patients
“Our research shows the benefits of this drug include significantly improving the health of even the sickest patients, allowing them to return to their normal life sooner.”
Patient-Centered Medical Home Care Approach Effective in Hepatitis C Treatment
“This primary care HCV treatment program shows real promise through its impressive outcomes for curing selected patients of HCV.”
17 US States’ High Hepatitis C Rates Are a Result of Public Policy Shortcomings, Report Says
Those who inject drugs are the segment of the population most susceptible to the disease, also known as HCV, many studies have shown.
Hepatitis C Hijacks Signaling-Pathway Proteins to Survive, Grow in the Body, Study Reports
Researchers discovered that HCV hijacked several proteins involved in key signaling pathways to ensure that it could copy itself.
Doctors Transplant Kidneys with Hepatitis C, Then Cure Recipients’ Infection
Last year, Penn Medicine researchers started a clinical trial (NCT02743897) to evaluate the viability of transplanting kidneys from HCV-infected donors to uninfected patients on the kidney waitlist.
RTT MolecularDX Launches Tests to Detect Drug-resistant Hepatitis Viruses
“We are most excited about our new, first-of-its-kind, HCV DR Test for Replication Complex Inhibitors (RCI) drug resistance in the NS5a gene.”
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis
The aim of this study was to assess the cost-effectiveness of directly acting antivirals (DAAs) in CHC elderly patients.
Hepatitis B and C patients more likely to develop Parkinson's disease
The viruses hepatitis B and C may both be associated with an increased risk of Parkinson's disease, according to a study published in the March 29, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
ContraVir Reports New Mechanism of Action for Hepatitis B Virus Inhibitor CRV431
New studies show that CRV431 potently blocks the interaction between hepatitis B surface antigen (HBsAg), a key HBV protein, and cyclophilin A, an important cellular protein.